Pseudouridine synthase 7 as a context-specific therapeutic target in cancer Authors: Karen Abundiz-Yañez, Luis Córdova-Bahena, Nohemí Salinas-Jazmín, Angel J Trejo-León, Marco A Velasco-Velázquez Published: 2026 ABSTRACT AbstractHuman pseudouridine synthase 7 (PUS7) catalyzes the isomerization of uridine to pseudouridine in RNA substrates. Although its catalytic region has been characterized, further studies are needed to clarify the mechanisms underlying its substrate recognition and specificity. PUS7 promotes tumor progression in glioblastoma, pancreatic adenocarcinoma, neuroblastoma, hepatocellular carcinoma, and colorectal cancer by altering RNA stability, translational fidelity, and splicing, ultimately regulating key oncogenic processes such as cell proliferation, self-renewal, metabolic reprogramming, and stress responses. Additionally, PUS7 can promote tumor progression through noncatalytic mechanisms, as observed in colorectal cancer, where it forms protein–protein complexes that activate oncogenic signaling pathways. Conversely, PUS7 exhibits tumor-suppressive functions in gastric carcinoma and papillary thyroid carcinoma by targeting mRNAs and miRNAs that regulate gene expression linked to reduced tumor aggressiveness. These findings indicate that PUS7 may represent a context-dependent therapeutic target and underscore the need for further research to clarify the molecular basis of its effects in cancer. Such knowledge may guide the development of new therapeutic strategies for PUS7-driven tumors.Significance StatementRecent studies reveal that dysregulated pseudouridine synthase activity contributes to the progression of malignancies such as glioblastoma, pancreatic adenocarcinoma, neuroblastoma, colorectal cancer, and hepatocellular carcinoma. Here, we review the pseudouridine synthase’s structure–function relationships and context-specific activities. The evidence discussed will help the development of selective therapeutic strategies targeting RNA modification pathways.Key words: Pseudouridine synthase 7, Pseudouridine, RNA pseudouridylation, Cancer therapeutic target, Pseudouridine synthase 7 inhibitor Introduction Coding and noncoding RNAs undergo more than 170 site-specific posttranscriptional chemical modifications to the 4 canonical nucleotides, a mechanism that expands their structural and functional diversity.1,2 Pseudouridine (Ψ), the first identified and most abundant RNA modification, is widespread across all 3 domains of life. It is found in various noncoding RNAs, including transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), small nuclear RNAs, and small nucleolar RNAs, as well as in thousands of sites within mRNAs.1, 2, 3 Pseudouridylation influences RNA stability, translational fidelity, pre-mRNA splicing, protein–RNA interactions, and cellular stress responses.2,4 Ψ is an isomer of uridine (U) in which the glycosidic bond links the ribose to the C5 atom of uracil instead of the N1 atom, resulting in an additional hydrogen bond donor at the N1 imino atom.3 This isomerization is catalyzed by 2 classes of enzymes: (1) guide RNA-dependent H/ACA small ribonucleoproteins (sRNPs) and (2) guide RNA-independent stand-alone pseudouridine synthases (PUSs). H/ACA sRNPs, found exclusively in archaea and eukaryotes, require an H/ACA small nucleolar RNA to specify the target site and an sRNP protein complex to catalyze U-to-Ψ isomerization.5 In contrast, stand-alone PUS enzymes, present across all domains of life, recognize specific sequences or structural motifs within the target RNA and catalyze pseudouridylation autonomously, without accessory RNAs, energy input, or cofactors. Pseudouridylation cooperates with other RNA modifications (m6A, m5C, m1A, and m7G) to regulate gene expression by modulating RNA stability, translation, and RNA–protein interactions.6 This epitranscriptomic crosstalk is particularly relevant in tumor progression. For instance, aberrant Ψ and m5C in tRNAs promote the accumulation of tRNA-derived fragments (tRFs), a class of noncoding RNAs, contributing to translational reprogramming in cancer stem cells.7 In hormone-dependent cancers such as ovarian cancer, m6A regulates transcripts involved in proliferation, metastasis, and chemoresistance,8,9 often converging with Ψ-mediated regulation on pathways such as phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT).10,11 Moreover, both Ψ and m6A reduce binding of the translational repressor PUM2 to its mRNA binding motif,12 indicating that combinatorial RNA modifications can reshape posttranscriptional gene regulation. Brief historical perspective of PUS PUS enzymes are classified into 6 families, 5 of which are named after their Escherichia coli homologs: TruA, TruB, TruD, RluA, and RsuA. Among these, RsuA has been identified only in bacteria, whereas the sixth family, Pus10, is exclusive to archaea and eukaryotes.13 In humans, 13 PUS enzymes have been characterized, all with direct orthologs in mice.14 Twelve are stand-alone PUS enzymes: PUS1, PUSL1, and PUS3 (TruA family); TRUB1 and TRUB2 (TruB family); PUS7 and PUS7L (TruD family); RPUSD1, RPUSD2, RPUSD3, and RPUSD4 (RluA family); and PUS10 (Pus10 family).15 The 13th enzyme, DKC1, is an RNA-dependent H/ACA sRNP that catalyzes Ψ synthesis in humans and mice. Although all human PUS enzymes catalyze Ψ formation, they exhibit divergence in sequence identity and evolutionary origin. The sequence identity among human PUS enzymes ranges from 11% to 30% (Fig. 1A). This divergence suggests that each enzyme has evolved distinct substrate specificities that enable the recognition of particular RNA targets and the execution of specialized biological functions.13 Despite their low sequence conservation, PUS families share a conserved catalytic core characterized by an eight-stranded β-sheet fold (Fig. 1B). Comparison of human PUSs and the proposed mechanism of pseudouridylation catalyzed by PUS7. (A) Percent identity matrix among human PUS enzymes. (B) Structures of representative enzymes with the common catalytic core highlighted in orange. (C) Amino acid sequence alignment of PUS7 and PUS7L. The catalytic aspartate and nearby residues are highlighted in a red box. (D) Chemical conversion of U to Ψ. (E) Mechanistic model of glycal intermediate formation. Two pathways are proposed: an aspartate-initiated deprotonation mechanism and a stepwise cleavage–deprotonation mechanism (see text in section 2 for details). All PUS enzymes, including DKC1, depend on a strictly conserved aspartate residue that is essential for catalysis, suggesting a shared evolutionary origin.3,16 In addition to this catalytic aspartate residue, other amino acids contribute to the reaction mechanism, although their specific identities vary among families. These include a positively charged lysine residue that forms a salt bridge with the catalytic aspartate, an aromatic residue that stacks with the target U, a nucleotide-stacking residue, and a hydrophobic residue.3,13 Notably, PUS7 and PUS7L share not only the conserved catalytic aspartate residue but also several positively charged residues flanking this site (Fig. 1C). The catalytic aspartate residue initiates the reaction by attacking the ribose of the target U, leading to detachment of the uracil base and formation of a glycal intermediate.17 The reaction proceeds through cleavage of the glycosidic C1′–N1 bond, rotation of the nucleobase, and formation of a new C1′–C5 bond (Fig. 1D). However, the atomic-level mechanism of pseudouridylation remains to be clarified. Among the proposed mechanisms, the glycal intermediate model is the most widely accepted. This mechanism begins with a base dissociation–rebound step, during which the uracil base detaches and subsequently rebinds. Formation of the glycal intermediate occurs during this stage through cleavage of the glycosidic bond and deprotonation of the ribose. Two mechanistic variants have been proposed for this step. In the stepwise cleavage–deprotonation mechanism, the C1′–N1 bond is cleaved, and the catalytic aspartate deprotonates the C2′ carbon of the ribose—events that may occur either sequentially or in a concerted manner. In the aspartate-initiated deprotonation mechanism, the aspartate first abstracts the C2′ proton; together with base detachment, this leads to the formation of a glycal intermediate characterized by a C1′–C2′ double bond (Fig. 1E). Beyond the conserved catalytic residues, PUS enzymes contain additional structural features, including α-helices and loops, that form characteristic regions known as the forefinger and thumb. Furthermore, unique structural elements—together with the enzyme’s cellular localization—contribute to defining the specific RNA targets of each PUS enzyme.13,17 The RNA substrates and functional distinctions among PUS enzymes are summarized in Table 1.3,18, 19, 20, 21, 22, 23, 24, 25 Table 1Summary of human and mouse PUS enzymesFamilyEnzyme (Human/Mouse)LocalizationSubstrateRecognition SequenceCatalytic Residue (Human/Mouse)TruAPUS1/Pus1Nucleus and mitochondriatRNA, mRNA, pre-mRNA, and snRNAHRU motif at the 5′ base of a bulged stem loopAsp 146Asp 142PUSL1/Pusl1MitochondriatRNA (predicted)Unknown or absentAsp 66Asp 66PUS3/Pus3NucleustRNA (U-38/39), mRNA, and miRNAUnknown or absentAsp 118Asp 119TruBTRUB1/Trub1Nucleus and mitochondriatRNA (U-55), mRNA, and other ncRNAGUΨCNANNCAsp 121Asp 109TRUB2/Trub2MitochondriatRNA (U-55) and mt-mRNAUnknown or absentAsp 98Asp 98TruDPUS7/Pus7NucleustRNA (U-13), tRNA fragments, mRNA, pre-mRNA, rRNA, and snRNAUNΨARAsp 294Asp 293PUS7L/Pus7lNucleusmRNAUnknown or absentAsp 339Asp 339RluARPUSD1/Rpusd1UnknownrRNA (predicted)Unknown or absentAsp 67Asp 67RPUSD2/Rpusd2UnknownmRNAUnknown or absentAsp 274Asp 287RPUSD3/Rpusd3MitochondriatRNA, mt-mRNA, and rRNAUnknown or absentAbsentAbsentRPUSD4/Rpusd4Nucleus and mitochondriarRNA, tRNA, mt-mRNA, and pre-mRNAUnknown or absentAsp 153Asp 153Pus10PUS10/Pus10Nucleus, cytoplasm, and mitochondriatRNA (U-54/55), mRNA, and pri-miRNA (in the nucleus)GUUCAm1AAUCAsp 344Asp 342H/ACA sRNPsDKC1/Dkc1NucleusrRNA, mRNA, snRNAAn H/ACA snoRNA targets the specific sequence of modification in the RNA substrateAsp 125Asp 125H, non-G base; N, any base; R, G or A; snRNA, small nuclear RNA; snoRNA, small nucleolar RNA. Summary of human and mouse PUS enzymes H, non-G base; N, any base; R, G or A; snRNA, small nuclear RNA; snoRNA, small nucleolar RNA. Interestingly, sequence analyses of PUS families reveal that synthases belonging to the TruD family share no detectable sequence similarity with other PUS families. However, structural studies indicate that TruD enzymes underwent a rearrangement of their secondary structure elements. This reorganization likely resulted from a circular permutation of the protein fold, possibly resulting from an early gene rearrangement event. The presence of TruD orthologs across all phyla, each retaining this rearrangement, supports the hypothesis that TruD was the first PUS family to diverge from the others. Key recent advances Structural features and functional insights into human PUS7 PUS7 (EC 5.4.99.-) is a versatile PUS capable of modifying a broad spectrum of RNA substrates. For example, human PUS7 targets numerous mRNAs—a property shared by few other eukaryotic PUSs.3,16 Human PUS7 is a 661-residue protein containing a structurally conserved catalytic domain (residues 99–645) that forms a V-shaped core, a hallmark of the TruD family.3 This domain comprises 2 major subdomains, the PUS domain and the TRUD domain, which together create a cleft that accommodates RNA substrates.3 Within this region, 3 insertions introduce structural variations relative to bacterial TruD family PUSs.3,16 The first insertion (residues 163–235) lies in the N-terminal region and is linked to 1 arm of the V-shaped core via a flexible linker.3 The second insertion (residues 382–577) is associated with the TRUD domain and is conserved among all TruD family members. In eukaryotic PUS7, this insertion contains a helix–turn–helix motif (residues 398–457), which is crucial for RNA positioning.3,16 The third insertion (residues 590–619) is located near the hinge region on the outer surface of the catalytic domain3 (Fig. 2A). Structure of the catalytic domain of human PUS7. (A) Structural representation of residues 108–649 (Protein Data Bank ID: 5KKP), with insertions I, II, and III colored in red, green, and blue, respectively. The helix–turn–helix (HTH) motif within insertion II is highlighted in orange. (B) Key residues involved in catalysis. The active site includes D294 and E141 (both shown in red), K133 (blue), F137 and F345 (both shown in cyan), and N343 (yellow). The inset shows the spatial arrangement of these residues. Disease-associated residues G128 and D503 (both in orange), located outside the active site, are highlighted. (C) Predicted binding mode of the PUS7 inhibitor C17, as determined by molecular docking. C17 is shown as green sticks. The N-terminal region of human PUS7 (residues 1–98) is intrinsically disordered and dispensable for RNA binding and pseudouridylation activity. A truncated variant lacking this region retains full enzymatic function.3 In contrast, deletion of the helix–turn–helix motif abolishes tRNA pseudouridylation without affecting RNA binding, indicating a specific role in substrate positioning.3 The function of the third insertion remains unclear; however, its conservation in both yeast and human PUS7 suggests that it contributes to the recognition of additional RNA substrates.3,16 The active site of PUS7 is located at the bottom of the V-shaped cleft formed by the PUS and TruD domains. The upper surface of the cleft is positively charged and likely involved in RNA interaction.3 The catalytic site, positioned at the bottom of the cleft, includes the essential residue D294. Other residues critical for catalysis include F137, K131, and the NxF motif (N343 and F345) (Fig. 2B).3 Mutational studies have confirmed the importance of these residues. Substitution of the catalytic aspartate with alanine abolishes pseudouridylation in both human (D294A) and yeast (D256A) enzymes.3,16 Mutations in the NxF motif also markedly reduce activity: the yeast N305A (N343 in humans) and F307A (F345 in humans) mutants exhibit up to a 50,000-fold decrease in catalytic efficiency.16 Interestingly, the F307Y mutation partially restores activity, suggesting that base stacking contributes to stabilizing the target U.16 In yeast Pus7, alanine substitutions of F67 (F137 in humans) and E71 (E141 in humans) reduce the catalytic rate by ∼200-fold.16 Similarly, replacing the lysine adjacent to the catalytic aspartate (K61 in yeast and K131 in humans) with alanine decreases pseudouridylation activity by about 40-fold.16 Two disease-associated PUS7 variants (G128R and D503Y) have been identified in humans. Residue G128 lies in a loop near the active site and is essential for function; the G128R mutation abolishes pseudouridylation despite maintaining strong RNA binding.3 D503, located at the base of the TRUD domain, appears crucial for protein stability, because the D503Y mutation disrupts protein production, preventing functional assessment.3 Individuals harboring loss-of-function PUS7 variants exhibit defective production of active tRFs and reduced sequestration of translation initiation factors eIF4A and eIF4G by those tRFs.26 Such disruptions lead to neurodevelopmental disorders characterized by intellectual disability, including Lesch–Nyhan syndrome and autism spectrum disorder.26 Given the involvement of PUS7 catalytic activity in human disease, inhibitors sharing a common structural scaffold have been identified.27 Although their precise binding mode remains unknown, molecular docking predicts that these inhibitors interact with the active site, forming hydrogen bonds with key residues such as the catalytic residue D294, L130 (adjacent to K131), R298, M377, and Q378 (the latter 2, opposite D294). Additionally, T647, located within the C-terminal domain, stabilizes the inhibitor–enzyme interaction (Fig. 2C). Although the catalytic region of PUS7 has been extensively characterized, the mechanisms underlying substrate recognition and specificity remain unresolved. Human PUS7 recognizes the consensus motif UNUAR (N = any nucleotide, R = G or A) in target RNAs, similar to the UGUAR motif recognized by yeast Pus7.3,16 However, despite the widespread occurrence of UNUAR sequences, fewer than 5% of Us within these motifs are pseudouridylated, implying that additional structural elements influence modification efficiency.3,16,26 Indeed, full-length tRNA structure is required for human PUS7 activity, whereas an additional hairpin structure is necessary for modification in small nuclear RNAs,3 underscoring the importance of RNA architecture in substrate recognition. In mRNAs, modified Us are more frequently found in less structured regions compared with highly structured ones.16 It has been proposed that substrate selection occurs during the modification step rather than during RNA binding.3,16 Future structural studies of PUS7–RNA complexes will be essential to elucidate the molecular basis of enzyme selectivity. Clinical relevance of PUS7 expression in cancer RNA pseudouridylation is a dynamic process that plays an indispensable role in the metabolism, distribution, and function of diverse RNAs in physiological conditions as well as in tumors. Elevated levels of Ψ have been detected in biological samples from patients with various types of cancer, where they correlate with advanced disease stages and poor therapeutic outcomes.28,29 Accordingly, Ψ has emerged as a promising biomarker for cancer diagnosis, monitoring, and prognosis. Moreover, dysregulated expression or activity of members of the PUS family has been implicated in tumorigenesis and cancer progression.2,29,30 PUS7-dependent pseudouridylation plays a key role in regulating RNA translation and stability. Consequently, alterations in PUS7 expression or catalytic activity can influence cancer onset and progression. PUS7 has been implicated in tumor initiation, maintenance, and progression across multiple malignancies, including glioblastoma (GB),31 neuroblastoma,32 colorectal cancer (CRC),33,34 hepatocellular carcinoma (HCC),35,36 non–small cell lung cancer,37 prostate cancer,38 ovarian cancer,39 and pancreatic ductal adenocarcinoma (PDA).36,40 Emerging clinical evidence supports the role of PUS7 as a prognostic biomarker and potential tool for patient stratification across multiple cancer types. Pan-cancer analyses show that PUS7 expression is associated with tumor progression and patient survival across multiple malignancies.36 In GB, increased PUS7 expression correlates with aggressive tumor features and reduced patient survival.31 In CRC, elevated PUS7 levels are associated with metastasis and unfavorable clinical outcomes.33,41 In HCC, PUS7 overexpression constitutes an independent prognostic factor for overall survival and disease progression.35 In non–small cell lung cancer, PUS7 expression correlates with poor prognosis.37 In pancreatic cancer, elevated PUS7 expression correlates with poor prognosis and reduced overall survival.33,36,40,42 Altogether, these findings indicate that PUS7 expression may help stratify patients according to disease aggressiveness and identify subgroups that could benefit from therapies targeting RNA pseudouridylation pathways. Conversely, PUS7 expression is downregulated in some neoplastic diseases, including gastric cancer, papillary thyroid carcinoma (PTC), and preleukemic syndrome. In gastric cancer, reduced PUS7 expression has been associated with enhanced tumor proliferation and poorer clinical outcomes, suggesting a potential tumor-suppressive role in this malignancy.43 In PTC, decreased PUS7 levels correlate with aggressive clinicopathological features, including advanced tumor stage and increased metastatic potential.44 In preleukemic syndrome, diminished PUS7 expression has been linked to impaired hematopoietic differentiation and disease progression, further supporting its context-dependent tumor-suppressive function.45 These observations indicate that the clinical significance of PUS7 is tumor-type dependent. Control of PUS7 expression The mechanisms controlling aberrant PUS7 expression in cancer remain to be fully elucidated. In MYC-driven cancers, PUS7 is transcriptionally regulated by the MYC oncoprotein, which promotes its transcription and overexpression.32 However, no additional regulatory mechanisms have been described to date. To address this gap, we performed a bioinformatic prediction of transcription factor binding sites within the region spanning −2000 to +500 bp relative to the reported transcription start site of the human PUS7 gene (ENSG00000091127). Potential binding sites were initially identified using position weight matrixes derived from the JASPAR CORE Vertebrates and HOCOMOCO v11 databases. To mitigate the high false-positive rate of traditional sequence scanning, hits were refined using a customized bioinformatics pipeline.46 This approach integrated the clustering of redundant binding sites with a random forest classifier to simulate the 3-dimensional genomic context (specifically evaluating CpG island density and GC transitions in flanking regions), thereby excluding computationally predicted sites lacking in vivo chromatin accessibility. As a result, we identified 529 transcription factors predicted to bind the proximal promoter with a P > .85, suggesting that multiple signaling pathways may regulate PUS7 expression. Comparison with 381 transcription factors reported in the TFLink database47 revealed 129 overlapping factors (Fig. 3A). Enrichment analysis of these 129 transcription factors using Enrichr48,49 and the DisGeNET data base50 showed significant enrichment in genes and proteins associated with cancer-related processes and tumor types (Fig. 3B). Putative regulators of PUS7 expression. (A) Venn diagram showing the overlap between transcription factors reported to bind the PUS7 promoter in the TFLink database and those predicted by bioinformatic analysis (motif scanning with a relative affinity score >0.80, coupled with random forest filtering, P > .85). Analysis was performed with the Bio.motifs module from the Biopython package (v1.87) and scikit-learn v1.7.2. The code and the thresholds employed are available at Ref [46]. (B) Enrichment analysis of the 129 overlapping transcription factors using the DisGeNET database. (C) Network analysis of transcription factors associated with the “Neuroblastoma” gene set. Edge thickness reflects the strength of evidence in the STRING data base, and the purple oval highlights core pluripotency transcription factors. (D) Scatter plot evaluating the epigenetic impact on PUS7 transcription. The plot shows the Spearman rank correlation between PUS7 promoter methylation (β value) and mRNA expression (log 2 transcripts per million) in patients with GB from The Cancer Genome Atlas cohort (n = 65). As an example, we analyzed the interaction network formed by these transcription factors within the “Neuroblastoma” gene set from DisGeNET using STRING.51 PUS7 was included to identify previously reported associations. Using a low interaction score threshold (0.25) and all evidence channels, only MYC showed a direct association with PUS7. In contrast, the transcription factors formed a densely connected network (Fig. 3C), suggesting cooperative regulation of PUS7 expression. Notably, we identified a subnetwork comprising the core pluripotency transcription factors MYC, SRY-box transcription factor 2, the homebox protein NANOG, and Krüppel-like factor 4. This finding supports a link between PUS7 expression and regulatory programs associated with cellular pluripotency. Consistently, increased MYC activity impairs neuronal differentiation, promoting the maintenance of an undifferentiated state.52 In line with this, PUS7 is highly expressed in GB stem cells (GSCs) compared with normal neural stem cells, where it is required for tumorigenesis.31 Furthermore, epigenetic regulation of PUS7 expression may contribute to cancer progression, although current evidence remains limited. Analysis of The Cancer Genome Atlas GB dataset revealed hypomethylation at the PUS7 promoter (β < 0.3), consistent with an active transcriptional state. However, no significant correlation was observed between promoter methylation and mRNA expression in GB samples (Fig. 3D). Similarly weak correlations were found in low-grade glioma, breast cancer, and lung adenocarcinoma, suggesting that DNA methylation at the promoter plays a limited role in the regulation of PUS7 expression in these tumor types. The importance of additional epigenetic and topological mechanisms remains to be determined. PUS7 is a context-dependent therapeutic target in cancer As described earlier, PUS7 has a well documented dual role in cancer progression. PUS7-mediated pseudouridylation promotes oncogenic functions, such as cancer cell pluripotency, metabolic reprogramming, and immune regulation in several malignancies.31,33,34,40,41 PUS7 also plays protumor roles in a catalytic-independent manner, by interacting with other proteins of the Wingless-related integration site (Wnt)/β-catenin pathway,34 PI3K/AKT/mammalian target of rapamycin (mTOR)41 pathway, or heat-shock responses.33 In contrast, PUS7 can inhibit tumor progression in other cancer types by inducing posttranslational modifications that affect mRNA translation efficiency,43 activity of tRFs,45 and functions of tsRNAs, pre-miRNAs, and miRNAs.44 The following sections summarize and discuss recent findings on the diverse role of PUS7 in tumorigenesis across different cancer types. Glioblastoma GB is the most common and aggressive primary brain tumor in adults, with a survival of <6 months if left untreated.53 PUS7 is significantly overexpressed in GB compared with normal brain tissue, and its high expression correlates with poorer survival outcomes in patients with GB.31 In a seminal study, Cui and colleagues31 demonstrated that PUS7 expression is further elevated in GSCs but not in neural stem cells. Knocking down or knocking out PUS7 in GSC lines derived from patients with grade IV GB reduced cell growth, self-renewal, and sphere formation, whereas PUS7 overexpression had the opposite effect,31 indicating that PUS7 plays a crucial role in promoting and maintaining stemness. Furthermore, reducing PUS7 expression inhibited xenograft tumor growth and prolonged host mouse survival.31 The authors demonstrated that the enzymatic activity of PUS7 is essential for its role in stemness, because the catalytically inactive D294A mutant of PUS7 does not enhance GSC proliferation or self-renewal and fails to support in vivo tumorigenesis.31 PUS7 promotes tumor growth through the pseudouridylation of specific tRNAs, enabling codon-specific translational control of key genes. For example, loss of PUS7 reduces pseudouridylation at critical tRNA sites, notably position 50 in tRNA-Arg-CCG-2-1. This modification is specific to GSCs and absent in neural stem cells. Despite these changes, tRNA stability and tRF levels remain unaffected by PUS7 knockout. Mechanistically, PUS7 regulates codon-specific translation of genes such as tyrosine kinase 2 through tRNA pseudouridylation, thereby influencing GSC function. PUS7 suppresses the signal transducer and activator of transcription 1 pathway, which normally restricts cell proliferation, and enhances tyrosine kinase 2 translation, further promoting tumor progression.31 Unlike previous studies suggesting global translational changes,45 PUS7 in GB selectively regulates the translation of specific targets. Moreover, PUS7 inhibition induces interferon-stimulated gene expression and reduces GSC self-renewal. Importantly, Cui and colleagues31 identified several small-molecule inhibitors of PUS7, among which compounds C4 and C17 exhibited the strongest inhibitory effects on enzymatic activity. However, C17 demonstrated greater potency in reducing GSC proliferation and better selectivity.31 Importantly, C17 reduces pseudouridylation at PUS7-dependent sites in tRNAs but not in rRNAs.31 C17 suppresses tumorigenesis and improves survival in mice xenografted with GSCs,31 offering a promising therapeutic strategy. However, it remains to be demonstrated whether C17 reduces tumor growth exclusively through PUS7 inhibition or via an alternative mechanism of action. These findings highlight the importance of PUS7-mediated RNA modifications in GB, validating PUS7 as a therapeutic target. Pancreatic adenocarcinoma PDA is one of the most lethal malignancies, characterized by poor prognosis and limited therapeutic options.54 Several studies have identified PUS7 as a tumor-promoting factor in PDA, where elevated PUS7 expression correlates with aggressive phenotypes and unfavorable clinical outcomes.33,36,42 Recent multiomics analyses have identified that elevated PUS7 expression correlates with poor prognosis and facilitates the generation of an immunosuppressive tumor microenvironment.40 Mechanistically, PUS7 induces the formation of neutrophil extracellular traps and macrophage polarization toward an immunosuppressive M2 phenotype.40 This PUS7–neutrophil extracellular trap–macrophage axis represents a previously unrecognized mechanism linking RNA pseudouridylation to immune evasion in PDA. Importantly, PUS7 forced silencing suppresses the growth of PDA xenotransplants and reduces the immunosuppressive microenvironment.40 The same study identified the small-molecule PUS7 inhibitors S428-1145, 3448-3245, and M042-0012. S428-1145 exhibited superior binding stability, stronger predicted interactions with the catalytic pocket, and more robust antitumor activity,40 leading to its selection for further experimental validation. Structural analysis reveals that S428-1145 contains 2 oxadiazole rings connected through a central piperidine moiety, forming an elongated molecular architecture with a hydrophobic aromatic group at one end and more polar functional groups at the opposite end. This arrangement suggests that S428-1145 may simultaneously interact with multiple regions of the PUS7 catalytic pocket. In contrast, the PUS7 inhibitor C1727 exhibits a compact and rigid aromatic scaffold, indicating a distinct binding mode within a more confined region of the enzyme. These findings identify a new role of PUS7 in the modulation of immune response in cancer and provide evidence that pharmacological inhibition of PUS7 disrupts the immunosuppressive tumor microenvironment in preclinical models of PDA. Thus, PUS7 is a promising therapeutic target for PDA treatment. Neuroblastoma Neuroblastoma is a clinically heterogeneous pediatric cancer that arises from neural crest cells. It is the most common extracranial solid tumor in children, with a prognosis that varies widely depending on multiple factors.55 PUS7 is a transcriptional target of the MYC oncoproteins and plays a role in neuroblastoma development. N-myc proto-oncogene protein (MYCN) directly binds to the PUS7 promoter, thereby stimulating its expression.32 Consistently, PUS7 expression is elevated in tumors of the MYCN-amplified subtype, and ectopic PUS7 overexpression enhances neuroblastoma cell proliferation and xenograft tumor growth.32 Silencing PUS7 leads to downregulation of genes involved in critical cellular processes, including the response to endoplasmic reticulum stress, tRNA aminoacylation, serine biosynthesis, one-carbon metabolism, and amino acid synthesis and transport.32 Further studies in neuroblastoma cells demonstrated that PUS7 regulates the pseudouridylation of (1) malignant T-cell-amplified sequence 1 mRNA, which promotes stress-induced expression of activating transcription factor 4, and (2) the 3′-untranslated region of activating transcription factor 4 mRNA.32 These effects collectively protect neuroblastoma cells from MYC-induced cellular stress by enabling activating transcription factor 4–mediated adaptive responses. Importantly, the PUS7 inhibitor C17 has shown potent cytotoxic activity against MYCN-amplified neuroblastoma cells, suggesting that pharmacological inhibition of PUS7’s catalytic activity may represent a promising therapeutic strategy for a subset of neuroblastoma patients. Colorectal cancer CRC is a leading cause of cancer-related mortality worldwide, characterized by high relapse rates and poor prognosis.56 PUS7 is significantly upregulated in human CRC tissues,41 and its elevated expression correlates with poor survival outcomes and increased metastatic potential.33 Consequently, PUS7 has been proposed as a potential therapeutic target for CRC. The protumorigenic role of PUS7 in CRC is partly attributed to its capacity to regulate tumor cell proliferation and survival. PUS7 overexpression promotes CRC cell proliferation, whereas its silencing reduces proliferation and/or induces apoptosis.34,41 Consistently, PUS7 knockdown suppresses CRC cell proliferation in vitro and inhibits tumor growth in vivo.34 Two primary mechanisms have been identified to explain how PUS7 promotes CRC progression. First, PUS7 exerts oncogenic effects through its interaction with sirtuin 1,34 a known activator of the Wnt/β-catenin signaling pathway.57 Within this cascade, Wnt3 appears to play a central role because its expression is markedly reduced following PUS7 silencing.34 Moreover, PUS7 overexpression increases the phosphorylation of PI3K, AKT, and mTOR in CRC cells.41 Given that the PI3K/Akt/mTOR signaling pathway is a key regulator of cellular quiescence, proliferation, and survival, these findings suggest that PUS7 drives tumor growth through concurrent activation of oncogenic signaling networks. Second, PUS7 enhances CRC cell migration and invasion through a catalytically independent mechanism involving the HSP90/LIM and SH3 protein 1 axis.33 PUS7 interacts with HSP90, a molecular chaperone that stabilizes PUS7 by preventing its proteasomal degradation.33 The resulting PUS7–HSP90 complex modulates LIM and SH3 protein 1, an oncogene known to regulate nuclear transcription by interacting with the epigenetic machinery—including UHRF1, DNMT1, and G9a—and the transcription factor Snail1.58 As a result, PUS7 overexpression promotes cytoskeletal reorganization, enhancing cell motility and ultimately facilitating metastasis.33 In agreement, PUS7 knockdown reduces CRC cell colony formation and invasion in vitro33 and partially suppresses HSP90-driven invasion and metastasis in vivo.33 Notably, combined treatment with an HSP90 inhibitor (NMS-E973) and PUS7 suppression provides a more effective strategy to limit metastasis.33 Recent evidence further implicates PUS7 in changes in mitochondrial RNA pseudouridylation. Li et al59 reported increased Ψ levels in mitochondrially encoded cytochrome b mRNA, which strongly correlate with PUS7 expression. These findings suggest that PUS7-mediated Ψ-mitochondrially encoded cytochrome b modification may influence the stability of mitochondrial oxidative phosphorylation complex III, thereby contributing to colon tumorigenesis. Although a direct causal relationship has not yet been established, this emerging connection warrants further investigation. Hepatocellular carcinoma HCC is the sixth most diagnosed cancer and the third leading cause of cancer-related mortality worldwide.60 Amuro et al61 demonstrated that serum Ψ and α-fetoprotein can serve as complementary biomarkers for HCC diagnosis. In patients with very small liver tumors, serum Ψ detected cases that α-fetoprotein missed, highlighting the potential utility of pseudouridylation quantification for early detection of HCC.61 Transcriptomic and proteomic data indicate that PUS7 expression is elevated in HCC compared with non-cancerous liver tissues.35,36 Furthermore, the PUS7 gene amplification occurs in approximately one-third of patients witht HCC, and its overexpression is associated with poor prognosis. High PUS7 levels constitute an independent risk factor for overall survival and disease progression.35 Interestingly, genomic data also reveal that a small subset of patients with HCC harbor PUS7 deletions, which are paradoxically associated with shorter overall survival.35 The biological basis of this observation remains unclear. Immune profiling studies show that PUS7 expression in HCC negatively correlates with the estimated intratumoral abundance of several immune cell types, including T helper 1 cells, neutrophils, natural killer cells, monocytes, macrophages, myeloid-derived suppressor cells, mast cells, eosinophils, activated B cells, and CD8+ T cells. In contrast, it positively correlates with T helper 2 cells and activated CD4+ T cells,35 suggesting that PUS7 may contribute to an immunosuppressive tumor microenvironment. The mechanisms underlying the protumorigenic effects of PUS7 in HCC have yet to be elucidated. A study using the HepG2 cell line identified PUS7 as the enzyme responsible for pseudouridylation of pre-mRNAs containing the UNΨAR motif.23 Ψ modifications in pre-mRNA can influence alternative splicing by altering interactions with small nuclear RNAs or RNA binding proteins, as well as by modifying pre-mRNA secondary structures.23 PUS7 silencing in HepG2 cells led to alternative splicing in 175 genes and differential expression in 374 genes.23 Notably, PUS7 modifies distinct pre-mRNA targets compared with PUS1 or RPUSD4.23 Collectively, these findings indicate that PUS7-mediated pseudouridylation plays a significant role in mRNA metabolism and gene regulation, potentially influencing HCC initiation and progression. PUS7 as a tumor suppressor In gastric cancer, PUS7 expression is significantly lower in tumor tissues compared with adjacent nontumor tissues.43 Functionally, PUS7 inhibits gastric cancer cell proliferation and xenograft tumor growth through its catalytic activity.43 Mechanistically, PUS7 exerts tumor-suppressive effects by regulating the expression of the α-ketoglutarate–dependent dioxygenase alkB homolog 3 (ALKBH3).43 Ectopic expression of wild-type PUS7, but not the catalytically inactive D294A mutant, increases pseudouridylation of ALKBH3 mRNA at the U696 site, enhancing its translation efficiency and thereby suppressing gastric tumor progression.43 Notably, forced expression of ALKBH3 recapitulates the antitumoral effects of PUS7 in vitro and in vivo,43 supporting the notion that the protective function of PUS7 in gastric cancer is mediated, at least in part, through ALKBH3 upregulation. In myelodysplastic syndromes, PUS7 is frequently lost, accompanied by abnormalities in chromosome 7, where the gene is located.62 Absence of PUS7 correlates with an increased risk of progression from myelodysplastic syndrome to acute myeloid leukemia.45 Consistently, PUS7 deletion in human embryonic stem cells disrupts the differentiation of hematopoietic stem and progenitor cells into erythroid and myeloid lineages.45 Mechanistically, PUS7-mediated pseudouridylation enhances the interaction between specific tRFs containing a 5′ mini-terminal oligoguanine motif (mTOG) and the poly(A)-binding protein 1, which participates in translation initiation. This interaction inhibits translation by blocking recruitment of the co-activator polyadenylate-binding protein-interacting protein 1, thereby reducing translation of transcripts with pyrimidine-rich 5′-untranslated regions, including terminal oligopyrimidine tract mRNAs encoding ribosomal and translational components.7,45 Loss of PUS7 impairs pseudouridylation of these tRFs, leading to uncontrolled protein synthesis, disrupted differentiation, and the development of hematologic malignancies such as acute myeloid leukemia.45 In PTC, PUS7 expression is downregulated relative to normal thyroid tissue and further reduced in metastatic compared with nonmetastatic PTC.44 Correspondingly, PTC and adjacent normal tissues exhibit differential Ψ content in tsRNAs, pre-miRNAs, and miRNAs.44 Functional studies identified pseudouridylation of pre-miR-8082 as a key event suppressing CD47 expression. Thus, reduced PUS7 expression or activity increases CD47 levels in PTC cells, promoting cell proliferation, adhesion, migration, and acquisition of a metastatic phenotype.44 Collectively, these findings demonstrate that PUS7 can function as a tumor suppressor in specific cancer contexts, primarily by maintaining proper RNA modification, translation control, and differentiation programs. Its loss or inactivation contributes to malignant transformation through dysregulated pseudouridylation-dependent pathways. Current challenges and knowledge gaps From a structural perspective, 2 main challenges remain. First, the structural and catalytic features of human PUS7 are still incompletely defined. Although 1 PUS7 structure has been deposited in the Protein Data Bank (ID: 5KKP), the free-energy landscape of the protein remains uncharacterized. As a result, additional conformations with potential biological relevance may exist but remain unexplored. Second, the structural basis of substrate recognition and selectivity requires further clarification. It is known that the helix–turn–helix domain is indispensable for RNA positioning but not for binding; however, the roles of the N-terminal region and the third insertion domain remain unclear. Given the low sequence identity between PUS7 and other family members, this information cannot be reliably extrapolated from other PUS enzymes. From a biological perspective, the relative contribution of PUS7—versus other PUSs—to the increased RNA pseudouridylation observed in cancer remains to be defined. PUS7 expression and activity have been implicated in promoting stemness in GB cells, immunosuppression in HCC, and differentiation in preleukemic cells, yet the underlying mechanisms are only partially understood. Moreover, it is unknown whether PUS7 similarly regulates CSC biology, immune responses, or differentiation programs in other tumor types. In CRC cells, PUS7 elicits tumor progression through protein–protein interactions and by modifying mitochondrial transcripts. These functions remain largely unexplored, and it is not known whether they are context-dependent or whether they cooperate with the canonical physiological roles of the enzyme. Finally, advancing our understanding of the structural and biological features of PUS7 requires efficient, sensitive, and broadly accessible detection methods. Such tools are still under development. Perspective on future directions PUS7 promotes malignant progression in certain types of cancer. Supporting its potential oncogenic role, nanopore sequencing in neuroblastoma cells revealed PUS7-dependent Ψ modifications across 1246 mRNAs encoding proteins involved in ribosome assembly, translation, and energy metabolism.63 Because these processes are frequently dysregulated in cancer, further studies are needed to evaluate the functional consequences of genetic or pharmacological modulation of PUS7 in additional cancer models. These studies should be conducted under clinically relevant conditions, such as in the presence of cytotoxic agents. For example, 5-fluorouracil, a widely used chemotherapeutic drug, can be incorporated into RNA, thereby altering PUS activity, reducing Ψ levels, and impairing ribosomal function.64 In tumors driven by PUS7, the enzyme constitutes a promising therapeutic target. Future research in these contexts should focus on (1) identifying additional mechanisms through which PUS7 induces phenotypic changes in cancer cells, including protein–protein interactions; (2) developing new PUS7-targeting drugs and assessing their efficacy and safety in relevant models of diverse tumors; and (3) identifying biomarkers that correlate with drug efficacy or toxicity to define pharmacodynamic parameters that could be eventually applied in clinical trials. The available structural information on the catalytic domain of PUS7 is sufficient to support the rational design of inhibitors targeting its enzymatic activity and the expansion of the chemical space of those compounds. However, developing inhibitors that disrupt PPIs will require the identification and characterization of PUS7-interacting proteins and the structural mapping of interaction interfaces within these complexes. The potential toxicity of pharmacological PUS7 inhibition warrants careful consideration, given its roles in development and stem cell biology. Efficacy of PUS7 inhibitors should be accompanied by low/manageable toxicity; therefore, risk–benefit assessment should be integrated early in preclinical development. Notably, tumors characterized by PUS7 overactivation predominantly arise in late adulthood, supporting a potentially acceptable therapeutic window. A key exception is pediatric neuroblastoma, in which the essential role of PUS7 in neurodevelopment32 raises concerns that therapeutic risks may outweigh potential benefits. Conclusions Emerging evidence identifies PUS7 as a potential biomarker and independent prognostic factor in several cancers. For example, its tumor-promoting role has been demonstrated in GB, neuroblastoma, PDA, CRC, and HCC, where PUS7 activates oncogenic signaling pathways and cellular functions through both catalytic-dependent and catalytic-independent mechanisms (Fig. 4A). Thus, PUS7 is a therapeutic target for generating new treatments for these tumors. Dual role of PUS7 in tumor progression. PUS7 supports cancer progression across different tumor types (left) through either catalytic-dependent or catalytic-independent mechanisms. On the contrary, PUS7 catalytic activity exerts antitumor effects in gastric carcinoma and PTC (right), by promoting the posttranscriptional regulation of genes that inhibit cellular processes associated with aggressive phenotypes. ATF4, activating transcription factor 4; NET, neutrophil extracellular trap; STAT1, signal transducer and activator of transcription 1; TYK2, tyrosine kinase 2. In another group of tumors—including non–small cell lung cancer, prostate cancer, and ovarian cancer37, 38, 39—transcriptomic and clinical data suggest that PUS7 may contribute to tumor progression, although the available information remains limited. Conversely, PUS7 exhibits tumor-suppressive functions in gastric carcinoma and PTC, by targeting mRNAs and miRNAs that regulate gene expression linked to reduced tumor aggressiveness (Fig. 4B). In these cases, inhibition of its catalytic activity should not be considered a therapeutic option. However, elucidating the molecular basis of PUS7-mediated tumor suppression may uncover novel therapeutic strategies for these cancers. Conflict of interest Luis Córdova-Bahena reports that financial support was provided by SECIHTI México. Nohemí Salinas-Jazmin reports that financial support was provided by SECIHTI México. All other authors declare no conflicts of interest. Acknowledgments No author has an actual or perceived conflict of interest with the contents of this article. We thank Patricia Cuautle-Rodríguez and Kevin Lugo-García for their assistance in figure preparation. Financial support Financial support was received by SECIHTI México, projects Cátedras CONACYT 639 (M.A.V.-V., and L.C.-B.) and SECIHTI-CF2023-I-92 (N.S.-J.). K.A.-Y. and A.J.T.-L. were supported with PhD scholarships from SECIHTI México. Data availability There are no datasets presented in this paper. CRediT authorship contribution statement Karen Abundiz-Yañez: Investigation, Visualization, Writing – Original draft. Luis Córdova-Bahena: Investigation, Visualization, Writing – Original draft. Nohemí Salinas-Jazmín: Investigation, Visualization, Writing – Original draft. Angel J. Trejo-León: Investigation, Visualization, Writing – Original draft. Marco A. Velasco-Velázquez: Conceptualization, Supervision, Writing – Review and editing. Declaration of AI and AI-assisted technologies in the writing process During the preparation of this work, the authors used ChatGPT in order to check grammar and improve readability. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the publication. References Associated Data Data Availability Statement There are no datasets presented in this paper.